Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyPresbyterian NGS Policy Coverage Update | OpenPaye…
    Ask Trek AI about this page
    CurrentPresbyterian Health PlanPolicy 29.0

    Genetic Testing: Next Generation Sequencing

    Customize your policy alerts

    Sign up for Presbyterian Health Plan Policy 29.0 alerts

    Get alerted when Policy 29.0 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This medical policy governs coverage and prior authorization for next-generation sequencing, including somatic and germline cancer testing, solid-tumor testing, and testing for myeloid malignancies or suspected myeloid malignancies. Coverage depends on the member's specific benefit plan and Schedule of Benefits and applies to Commercial, Medicaid, and Medicare products.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyGenetic Testing: Next Generation Sequencing
    Policy CodePolicy N/A
    Change TypeAnnual review with coding updates
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization through Pres Online before requesting NGS testing for Commercial, Medicaid, or Medicare members.
    SourceLink
    POLICY UPDATE CHANGES

    The 2025 annual review added CPT/PLA codes 0523U, 0473U, 0543U, and 0211U for NGS testing and requires prior authorization for them.

    The policy continues prior authorization for the listed NGS, solid-tumor, and myeloid-malignancy testing codes.

    The policy replaced CPT 81455 with CPT 81479 for the xT CDx colorectal-cancer and solid-organ-neoplasm laboratory test effective April 28, 2023.

    Required

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Prior authorization
    3Covered NGS categories
    20+NGS-related codes
    05/28/2025Last review

    Coverage Criteria

    Covered NGS Indications

    Covered NGS indications include the following categories, subject to the applicable CMS National Coverage Determination (NCD), Local Coverage Determination (LCD), and Local Coverage Article (LCA).

    ONE of the following covered NGS indications

    • Somatic (acquired) cancer testing under NCD 90.2.
    • Germline (inherited) cancer testing under NCD 90.2.
    • Solid-tumor testing under MolDX LCD L38158 and LCA A57858.
    • Myeloid malignancies and suspected myeloid malignancies under LCD L38176 and LCA A57878 for NGS laboratory-developed testing.

    Presbyterian Health Plan (PHP) follows MolDX LCD L38158 and LCA A57858 for NGS testing of solid tumors. This coverage is specific to solid-tumor testing and excludes hematologic malignancies, circulating tumor DNA (ctDNA) testing, and other cancer-related uses of NGS, including germline testing in or for patients with cancer.

    PHP follows NCD 90.2 for covered NGS indications involving somatic (acquired) cancer and germline (inherited) cancer. PHP also follows LCD L38176 and LCA A57878 for NGS laboratory-developed testing for myeloid malignancies and suspected myeloid malignancies.

    Coding and Code Sets

    Covered NGS and Solid-Tumor Testing CPT CodesCPTCovered
    0037UTargeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden; includes FoundationOne CDx (F1CDx).
    0022UOncomine Dx Target: targeted genomic sequence analysis panel for non-small cell lung neoplasia, DNA and RNA analysis, 23 genes, interrogation for sequence variants and rearrangements, reported as presence/absence of variants and associated therapies to consider.
    0111UPraxis: extended RAS panel test for oncology, targeted KRAS codons 12, 13, and 61 and NRAS codons 12, 13, and 61 gene analysis using formalin-fixed paraffin-embedded tissue.
    0172UNGS code added as a CMS NCD 90.2 code; description is not reproduced in the current coding text.
    0239UFoundationOne Liquid CDx; description is not fully reproduced in the current coding text.
    0242UGuardant360 CDx: targeted genomic sequence analysis panel for solid organ neoplasm using cell-free circulating DNA, analysis of 55-74 genes, including sequence variants, gene copy number amplifications, and gene rearrangements.
    0523UoncoReveal CDx Oncology, solid tumor, DNA qualitative NGS of SNVs and insertion/deletions in 22 genes using formalin-fixed paraffin-embedded tissue, reporting presence or absence, location, nucleotide change, and amino-acid change.
    0473UxT CDx, Tempus: oncology solid-tumor NGS of DNA from formalin-fixed paraffin-embedded tissue with comparative sequence analysis from matched normal blood or saliva, 648 genes, including sequence variants, insertions/deletions, copy-number variants, rearrangements, microsatellite instability, and tumor mutational burden.
    0543UTruSight Oncology Comprehensive: solid-tumor NGS of DNA from formalin-fixed paraffin-embedded tissue of 517 genes, with DNA sequence variants, insertions/deletions, RNA fusions in 24 genes, one splice variant, and tumor mutational burden.
    0211UNGS code added in the 2025 annual review; description is not reproduced in the current coding text.
    1–10 of 20
    1/2
    Covered Myeloid and Hematolymphoid Malignancy Testing CPT CodesCPTCovered
    81450Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants, copy number variants or rearrangements, or isoform or mRNA expression levels, if performed; DNA analysis or combined DNA and RNA analysis.
    81451Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; DNA analysis or combined DNA and RNA analysis.
    Unlisted or Replaced Molecular Pathology CPT CodesCPT
    81479Unlisted molecular pathology procedure.
    81455Prior xT CDx code; publication history states it was replaced by 81479 for the xT CDx colorectal-cancer and solid-organ-neoplasm laboratory test effective 04/28/2023.

    Provider Actions and Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for genetic testing covered under this policy. Submit the request through Pres Online for Commercial, Medicaid, and Medicare members.

    • Submit through Pres Online: https://ds.phs.org/preslogin/index.jsp
    • Applies to Commercial, Medicaid, and Medicare members.
    Prior Authorization

    New Advanced-Cancer NGS Codes

    For advanced-cancer NGS under NCD 90.2 for ALOB, the following codes were added in the 2025 annual review and require prior authorization.

    • 0523U
    • 0473U
    • 0543U
    • 0211U

    Background

    Next-generation sequencing (NGS) measures one or more genetic variations and may be used as a companion in vitro diagnostic test for a therapeutic product. For patients with recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer, tumor genetic variations combined with clinical factors may help predict response to treatment; testing is ideally performed before treatment initiation.

    Definitions

    In vitro companion diagnostic laboratory test
    PurposeProvides test results about genetic variations.
    Clinical roleSupports the safe and effective use of a corresponding therapeutic product.
    UseMay be used as a companion diagnostic test for a therapeutic product.
    Next Generation Sequencing (NGS)
    DefinitionA sequencing technique used in a laboratory diagnostic test.
    What it measuresOne or more genetic variations.
    Clinical application

    Covered Indication Categories

    Somatic and Germline Cancer Testing Under NCD 90.2

    Coverage is available when the testing meets the applicable NCD requirements.

    NCD 90.2 cancer testing: Testing is for somatic (acquired) cancer or germline (inherited) cancer under NCD 90.2.

    The policy follows NCD 90.2; detailed NCD criteria are not reproduced in this policy.

    Next-Generation Sequencing for Solid Tumors Under MolDX LCD L38158 and LCA A57858

    Coverage is available when the testing is specific to a solid tumor and meets the applicable MolDX requirements.

    Solid-tumor NGS: Testing is for a solid tumor under MolDX LCD L38158 and LCA A57858.

    This category excludes hematologic malignancies, circulating tumor DNA testing, and other cancer-related uses of NGS, including germline testing in or for patients with cancer.

    NGS Laboratory-Developed Testing for Myeloid Malignancies and Suspected Myeloid Malignancies Under LCD L38176 and LCA A57878

    Not Covered Uses

    The following uses are not covered under the solid-tumor NGS category: testing for hematologic malignancies, circulating tumor DNA (ctDNA) testing, and other cancer-related NGS uses, including germline testing in or for patients with cancer.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyGenetic Testing: Next Generation Sequencing
    Policy CodePolicy N/A
    Change TypeAnnual review with coding updates
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization through Pres Online before requesting NGS testing for Commercial, Medicaid, or Medicare members.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Code SetsProvider Actions and RequirementsBackgroundDefinitionsCovered Indication CategoriesNot Covered Uses
    Prior Authorization

    Continuing Prior Authorization Code Set

    The following NGS and solid-tumor testing codes continue to require prior authorization for ALOB under the applicable coverage guidance.

    • 0037U
    • 0022U
    • 0111U
    • 0172U
    • 0239U
    • 0242U
    • 81479
    • 81445
    • 81450
    • 81451
    • 0244U
    • 0250U
    • 0329U
    • 0334U
    • 81449
    • 0391U
    • 0379U
    • 81457
    • 81458
    • 81459
    Documentation Required

    Coverage-Supporting Documentation

    Maintain and provide documentation supporting coverage under the applicable National Coverage Determination, Local Coverage Determination, Local Coverage Article, or related policy. Additional information supporting medical necessity may be submitted when criteria are not met.

    • Applicable guidance includes NCD 90.2, LCD L38158, LCA A57858, LCD L38176, and LCA A57878.
    • Providers are expected to maintain or have access to appropriate documentation when requested.
    Documentation Required

    Clinical Indication and Disease Documentation

    Document the clinical indication for testing and the member’s cancer diagnosis and disease context. Relevant context may include recurrent, relapsed, refractory, metastatic, or advanced stage III or IV disease, as applicable.

    • Specify whether testing addresses somatic (acquired) or germline (inherited) cancer indications.
    • Include the disease context and intended treatment-related use of the NGS results.
    Note

    Benefit-Plan Limitations

    Coverage is subject to the member’s specific benefit plan and Schedule of Benefits. Benefits may be broader or more limited than this policy, and the service may not be covered on every plan.

    • Verify the member’s benefit plan before ordering or billing.
    • Plan-specific limitations or exclusions may apply.
    Denial Risk

    Missing Authorization or Coverage Basis

    Claims may be denied when required prior authorization is missing or when the testing does not meet the applicable NCD, LCD, LCA, or related coverage criteria.

    • Obtain prior authorization before testing when required.
    • Submit documentation establishing the applicable coverage basis and medical necessity.
    Denial Risk

    Excluded Solid-Tumor NGS Uses

    Solid-tumor NGS coverage under LCD L38158 and LCA A57858 is limited to solid-tumor testing and excludes other cancer-related NGS uses.

    • Hematologic malignancies are excluded from this solid-tumor coverage provision.
    • Circulating tumor DNA (ctDNA) testing is excluded.
    • Germline testing in or for patients with cancer and other excluded cancer-related NGS uses are not covered under this solid-tumor provision.
    May be used as a companion in vitro diagnostic test to help predict response to a treatment.
    Somatic (acquired) cancer
    DefinitionGenetic alterations acquired in cancer cells.
    InheritanceNot inherited through the germline.
    Coverage contextSomatic cancer testing is included among the NGS coverage indications under NCD 90.2.
    Germline (inherited) cancer
    DefinitionGenetic alterations inherited through the germline.
    Clinical significanceAssociated with cancer susceptibility or inherited cancer syndromes.
    Coverage contextGermline cancer testing is included among the NGS coverage indications under NCD 90.2.

    Coverage is available when the testing meets the applicable LCD and LCA requirements.

    Myeloid malignancy NGS: Testing is for a myeloid malignancy or suspected myeloid malignancy under LCD L38176 and LCA A57878.

    The testing must be NGS laboratory-developed testing for myeloid malignancies or suspected myeloid malignancies.